Synergistic antitumor activity of lenalidomide with the BET bromodomain inhibitor CPI203 in bortezomib-resistant mantle cell lymphoma
In this paper, Dr. Gael Roué and his colleagues at the IDIBAPS in Barcelona and scientists from Constellation Pharmaceuticals presented evidence of a synergistic anti-tumor activity of lenalidomide in combination with a BET inhibitor in bortezomib-resistant mantle cell lymphoma cell lines. They show that exacerbated IRF4/MYC signaling is associated to bortezomib resistance in MCL in vivo and warrant clinical evaluation of lenalidomide plus BET inhibitor combination in MCL cases refractory to proteasome inhibition.